Characterization of the IFN-γ T-cell responses to immediate early antigens in humans with genital herpes

Virology Journal

Volumn 3, Issue , 2006, Pages

  Braun, Ralph P ^a,d   Payne, Lendon G ^b,d   Dong, Lichun ^c,d  

^a WYETH RESEARCH   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PowderJect Vaccines Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; GAMMA INTERFERON; GD ANTIGEN; ICP0 ANTIGEN; ICP22 ANTIGEN; ICP27 ANTIGEN; ICP4 ANTIGEN; PEPTIDE LIBRARY; PROTEIN VP22; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; VIRUS STRAIN;

ADULT; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON-GAMMA; MALE; MIDDLE AGED;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2;

EID: 33747046695     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-54     Document Type: Article

References (38)

1. Tao G, Kassler WJ, Rein DB: Medical care expenditures for genital herpes in the United States. Sex Transm Dis 2000, 27:32-38.
2. Liesegang TJ: Herpes simplex virus epidemiology and ocular importance. Cornea 2001, 20:1-13.
3. Tran T, Druce JD, Catton MC, Kelly H, Birch CJ: Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004, 80:277-279.
4. Roberts CM, Pfister JR, Spear SJ: Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003, 30:797-800.
5. Miller CS, Danaher RJ, Jacob RJ: Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Crit Rev Oral Biol Med 1998, 9:541-562.
6. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ: Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000, 30:549-566.
7. Koelle DM, Corey L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003, 16:96-113.
8. Milligan GN, Dudley-McClain KL, Young CG, Chu CF: T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. J Reprod Immunol 2004, 61:115-127.
9. Deshpande SP, Kumaraguru U, Rouse BT: Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2000, 2:973-978.
10. Posavad CM, Koelle DM, Shaughnessy MF, Corey L: Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997, 94:10289-10294.
11. Khanna KM, Lepisto AJ, Decman V, Hendricks RL: Immune control of herpes simplex virus during latency. Curr Opin Immunol 2004, 16:463-469.
12. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L: CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001, 166:4049-4058.
13. Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, Triezenberg SJ: Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994, 68:2803-2810.
14. Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL: Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 2000, 164:5167-5176.
15. Tigges MA, Leng S, Johnson DC, Burke RL: Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol 1996, 156:3901-3910.
16. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138.
17. Tobery TW, Wang S, Wang XM, Neeper MP, Jansen KU, McClements WL, Caulfield MJ: A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 2001, 254:59-66.
18. Milligan GN, Bernstein DI: Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229:259-268.
19. Liu T, Khanna KM, Carriere BN, Hendricks RL: Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001, 75:11178-11184.
20. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL: Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003, 18:593-603.
21. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL: CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191:1459-1466.
22. Koelle DM, Frank JM, Johnson ML, Kwok WW: Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 1998, 72:7476-7483.
23. Byars NE, Fraser-Smith EB, Pecyk RA, Welch M, Nakano G, Burke RL, Hayward AR, Allison AC: Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994, 12:200-209.
24. Eisenberg RJ, Cerini CP, Heilman CJ, Joseph AD, Dietzschold B, Golub E, Long D, Ponce de Leon M, Cohen GH: Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol 1985, 56:1014-1017.
25. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993, 11:213-244.
26. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260:157-172.
27. Looker KJ, Garnett GP: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 2005, 81:103-107.
28. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JMJ, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama 1999, 282:331-340.
29. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin G: Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40:1271-1281.
30. Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, Meseda CA, Snow DC, Wald A, Corey L: Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003, 100:12899-12904.
31. Simmons A, Tscharke DC: Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 1992, 175:1337-1344.
32. Koelle DM, Liu Z, McClurkan CM, Topp MS, Riddell SR, Pamer EG, Johnson AS, Wald A, Corey L: Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002, 110:537-548.
33. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O, Strupp M, Arbusow V, Brandt T: Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003, 163:2179-2184.
34. Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP: Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 2002, 99:978-983.
35. Yasukawa M, Yakushijin Y, Furukawa M, Fujita S: Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J Virol 1993, 67:6259-6264.
36. Mikloska Z, Cunningham AL: Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998, 79 ( Pt 2):353-361.
37. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L: Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101:1500-1508.
38. Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, Wagner SJ, Wu MS, Payne LG, Haynes JR: Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 2002, 76:4536-4546.